A total of 60 adult male SD rats weighing 200–250 g were divided into six groups using a random number table: the control group, AOH group, miR-93-5p agomir group with AOH (miR-93-5p+AOH), miR-93-5p agomir negative control group with AOH (miR-93-5p NC+AOH), siPDCD4 group with AOH (siPDCD4+AOH), and siRNA negative control group with AOH (siRNA NC+AOH).
miR-93-5p agomir (chemically modified miRNA agonist), siPDCD4 (chemically modified small interfering RNA sequence inhibiting PDCD4 expression), agomir NC, and siRNA NC (random sequence) were synthesized by Sangon Biotech. miR-93-5p agomir, siPDCD4, agomir NC, and siRNA NC (0.5 nmol/μl) were injected into the vitreous cavity of the corresponding group of AOH rats 30 min before modeling. Intravitreal injection was performed according to previous literature reports (36 (link), 54 (link)). Briefly, intravitreal injection was performed between two vortex veins about 1 mm from the corneal limbus.
miR-93-5p agomir (chemically modified miRNA agonist), siPDCD4 (chemically modified small interfering RNA sequence inhibiting PDCD4 expression), agomir NC, and siRNA NC (random sequence) were synthesized by Sangon Biotech. miR-93-5p agomir, siPDCD4, agomir NC, and siRNA NC (0.5 nmol/μl) were injected into the vitreous cavity of the corresponding group of AOH rats 30 min before modeling. Intravitreal injection was performed according to previous literature reports (36 (link), 54 (link)). Briefly, intravitreal injection was performed between two vortex veins about 1 mm from the corneal limbus.